DURHAM – Durham quantum computing biotechnology startup Polarisqb has inked a collaboration agreement with Allosteric Bioscience, a newly formed company, to develop novel pharmaceuticals.
The companies announced the deal in a statement.
The purpose: Improving human aging and longevity.
“Improved Aging, Longevity and Aging related diseases is a lead program at Allosteric Bioscience and the focus of this agreement, supported by an investment in Polarisqb,” the statement reads.
The joint program will use quantum computing and artificial intelligence to create “an inhibitor of a key protein involved in Aging that could have benefits for health representing a multibillion-dollar market,” the companies said.
“Quantum Computing technology is coming of age, allowing us to revolutionize drug discovery timelines, while improving the overall profile of the designed drugs,” said Dr. Shahar Keinan, CEO of Polarisqb. ” The application of Quantum Computers to solving these complex questions is extraordinary.”
Polarisqb raised funds in 2020, according to SEC filings.